"I need to make swift, clever decisions in the face of challenges to my pipeline."
Pharmaceutical R&D has never felt more like the front line. Not only is the pipeline shrinking, but proposed changes to patent rules can limit your ability to build a portfolio, and sustain market share. As innovation stalls, generics pour into the markets you need to address.
With decades of experience in collecting and analyzing essential data, Thomson Reuters knows the industry — both the way it stands now, and the trends that will drive successful innovation in the future.
We can help you identify emerging technology that will positively impact efficiency and cost, growing sectors where the real advances are taking place, and the geographic locations to base your research personnel and trials. We’ll highlight specialty and niche therapies that do not require large-scale trials and are not encumbered by competition, and the gaps in your portfolio that could be filled by research, partnerships and licensing-in.
You’ll find it easy to spin your thoughts into new areas, new lines of inquiry, new fields of study. With Thomson Reuters informing your decisions, you’ll promote scientific breakthrough throughout your teams.
Your data-mining efficiency will improve dramatically, gaining you time to do what you really want to do — ground-breaking research.
Real world solution
An R&D team has identified a potential drug target for cystic fibrosis and decides to focus on this target to develop a therapeutic agent.
The team uses Thomson Reuters solutions to gain a deeper understanding of the current market position in this field and to help validate the target.
Who can benefit
Biologists
Chemists
Competitive intelligence professionals
Intellectual property professionals
Licensing and business development